This was consistent with the analysis of CLL and AML patients that relapsed on venetoclax therapy, as well as with other published studies seeking to identify resistance factors to BCL-2 inhibitors [22, 23, 25–29]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.